The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update.

Ramsey LB, Johnson SG, Caudle KE, Haidar CE, Voora D, Wilke RA, Maxwell WD, McLeod HL, Krauss RM, Roden DM, Feng Q, Cooper-DeHoff RM, Gong L, Klein TE, Wadelius M, Niemi M
Clin Pharmacol Ther. 2014 96 (4): 423-8

PMID: 24918167 · PMCID: PMC4169720 · DOI:10.1038/clpt.2014.125

Simvastatin is among the most commonly used prescription medications for cholesterol reduction. A single coding single-nucleotide polymorphism, rs4149056T>C, in SLCO1B1 increases systemic exposure to simvastatin and the risk of muscle toxicity. We summarize evidence from the literature supporting this association and provide therapeutic recommendations for simvastatin based on SLCO1B1 genotype. This article is an update to the 2012 Clinical Pharmacogenetics Implementation Consortium guideline for SLCO1B1 and simvastatin-induced myopathy.

MeSH Terms (10)

Drug Interactions Genotype Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors Liver-Specific Organic Anion Transporter 1 Muscular Diseases Organic Anion Transporters Pharmacogenetics Polymorphism, Genetic Simvastatin

Connections (1)

This publication is referenced by other Labnodes entities: